Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data

(2021) Sean Wharton et al.   INTERNATIONAL JOURNAL OF OBESITY

Once-Weekly Semaglutide in Adults with Overweight or Obesity

(2021) John P.H. Wilding et al.   NEW ENGLAND JOURNAL OF MEDICINE

Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5

(2020) Robert F. Kushner et al.   Obesity

SELECT (Semaglutide effects on cardiovascular outcomes in people with overweight or obesity) rationale and design

(2020) Donna H. Ryan et al.   AMERICAN HEART JOURNAL

Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials

(2019) V. R Aroda et al.   DIABETES & METABOLISM

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2019) John B. Buse et al.   DIABETES CARE

MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?

(2019) Michael A Nauck et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial

(2018) Helena W Rodbard et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Maintenance of Lost Weight and Long-Term Management of Obesity

(2018) Kevin D. Hall et al.   MEDICAL CLINICS OF NORTH AMERICA

Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial

(2018) Patrick M O'Neil et al.   LANCET

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2018) Melanie J. Davies et al.   DIABETES CARE

Physical Function Following a Long-Term Lifestyle Intervention Among Middle Aged and Older Adults With Type 2 Diabetes: The Look AHEAD Study

(2017) Denise K Houston et al.   JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES

Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial

(2017) Bo Ahrén et al.   Lancet Diabetes & Endocrinology

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial

(2017) Vanita R Aroda et al.   Lancet Diabetes & Endocrinology

Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials

(2016) Karolin Bettge et al.   DIABETES OBESITY & METABOLISM

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Persistent metabolic adaptation 6 years after “The Biggest Loser” competition

(2016) Erin Fothergill et al.   Obesity

Impact of obesity and type 2 diabetes on health-related quality of life in the general population in England

(2016) Stephen Gough et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes

(2015) Melanie J. Davies et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

(2015) Xavier Pi-Sunyer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Modeling the clinical and economic implications of obesity using microsimulation

(2015) W. Su et al.   JOURNAL OF MEDICAL ECONOMICS

The importance of weight management in type 2 diabetes mellitus

(2014) J. P. H. Wilding   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes

(2013) P. Hollander et al.   DIABETES CARE

Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes

(2011) R. R. Wing et al.   DIABETES CARE

Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

Long-Term Persistence of Hormonal Adaptations to Weight Loss

(2011) Priya Sumithran et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Randomized Study on the Effect of Weight Loss on Obstructive Sleep Apnea Among Obese Patients With Type 2 DiabetesThe Sleep AHEAD StudyEffect of Weight Loss on Obstructive Sleep Apnea

(2009) Gary D. Foster   ARCHIVES OF INTERNAL MEDICINE